Malignant Melanoma Completed Phase 2 Trials for Trametinib (DB08911)

Also known as: Melanoma, Malignant / [M]Malignant melanoma NOS / Melanoma / Melanoma malignant

IndicationStatusPhase
DBCOND0029825 (Malignant Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02296996Dabrafenib and Trametinib for BRAF-inhibitor Pretreated PatientsTreatment